← AbCellera Biologics Inc. (ABCL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
AbCellera Biologics Inc. (ABCL)
Pharmaceutical Preparations · market cap $3.8B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
AbCellera Biologics (ABCL) is a Vancouver-based antibody discovery company with a proprietary single-cell screening platform, best known for its pandemic-era work under DARPA's Pandemic Prevention Platform. The company has transitioned its commercial focus toward its own pipeline, with lead asset ABCL635 in Phase 2 for vasomotor symptoms (hot flashes) associated with menopause. With $77.1M cash and an estimated 6.9-month runway, the company faces a near-term financing overhang ahead of a Phase 2 readout expected around February 2027.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-02-15 (est.)Phase 2 · ABCL635imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABCL635 | Phase 2 | Vasomotor Symptoms Associated With Menopause |
| Bamlanivimab | Phase 2 | COVID-19 |
Price & technical context
3-month
+71.5%
6-month
+296.3%
12-month
+176.5%
52-wk range
$2.78–$14.82
vs 50-day MA
+34.1%
vs 200-day MA
+134.5%
Realized vol
83.0%
Max drawdown
-54.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABCL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.